JPRN-UMIN000014009已完成未知
A phase 1 clinical pharmacological study with repeated oral doses of KAG-308 - A phase 1 clinical pharmacological study of KAG-308
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 45years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1. The subject with failure or medical history of central nervous system disease, cardiac disease, or failure of cardiovascular, respiratory, blood and hematopoietic function system, gastrointestinal system, liver and renal function, thyroid function, pituitary function, adrenal function, etc. And the subject concluded by principal investigator (or sub investigators) difficult to ensure safety during the study. 2. The subject who meet the criteria of "clinical laboratory test, vital sign, 12 lead electrocardiograms". 3. The subject who tested positive after either HIV test, HBV test, HCV test, syphilis test, or tuberculosis test. 4. The subject with medical history of gastrointestinal tract symptom or gastrointestinal tract resection that affects pharmacokinetics. 5. The subject who is using drug or receiving therapy. 6. The subject with drug allergy or medical history. 7. The subject who felt sick at the time of blood donation or blood collection. 8. The subject who had been taken blood (blood donation, etc.) of more than 400 mL 90 days before the starting day of administration of the study drug, or the subject with the annual volume of blood collection more than 1200 mL including this study. 9. The subject who cannot stop either drinking alcohol during hospitalization or smoking from the day before the date of admission until the day of discharge. 10. The subject who tested positive on a urine abusable drug test. 11. The subject who is administered other study drug within 112 days past (16 weeks) before the scheduled administration date of the study drug. 12. The stuff of the institution or employees of the sponsor. 13. The subject who participated in the clinical trial of KAG-308 in the past, and take a dose of study drug.
研究者
相似试验
进行中（未招募）
不适用
Phase II clinical study for the therapy of cystic fibrosis patients with aspecific mutatioCystic fibrosis patients with F508del-CFTR in homozygous or compound heterozygous with Class I or II mutationsEUCTR2013-001258-82-ITEuropean Institute for Cystic Fibrosis Research (IERFC)
已完成
1 期
Phase I/II study on the safety and efficacy of repeated administration of FIT039 transdermal patch for verrucas caused by human papilloma-virusPhase I/II study on the safety and therapeutic efficacy of repeated administration of FIT039 transdermal patch on verrucas caused by human papillomavirusJPRN-UMIN000029695Department of Dermatology, Kyoto University Hospital44
尚未招募
1 期
Trial Aimed at Reducing Complications After Half-Matched BMT for ThalassemiaCTRI/2019/04/018379Manashi Chakrabarti Foundation
已完成
1 期
A pharmacokinetic phase I study to assess the effect of different application sites on the pharmacokinetics of testosterone from a Testosterone Metered Dose (MD) Lotion in hypogonadism.HypogonadismMetabolic and Endocrine - DiabetesACTRN12605000518662Acrux DDS Pty Ltd12
已完成
不适用
A study to evaluate the pharmacokinetic and pharmacodynamic equivalence of HSP-130 and United States-approved Neulasta (Registered Trademark) and European Union-approved Neulasta (Registered Trademark) administered as a single subcutaneous dose to healthy volunteers.The study will be conducted in healthy subjects. Neulasta is indicated for the treatment of cancer chemotherapy-induced neutropenia.Cancer - Any cancerACTRN12615001049561Hospira, Inc.150